Ocumetics Technology Corp. Stock

Equities

OTC

CA67577H1047

Office Equipment

Delayed Toronto S.E. 11:24:05 2024-04-25 am EDT 5-day change 1st Jan Change
0.345 CAD +1.47% Intraday chart for Ocumetics Technology Corp. +11.29% +1.47%
Sales 2022 - Sales 2023 - Capitalization 40.28M 55.19M
Net income 2022 -2M -2.74M Net income 2023 -3M -4.11M EV / Sales 2022 -
Net cash position 2022 602K 825K Net Debt 2023 85.81K 118K EV / Sales 2023 -
P/E ratio 2022
-19.8 x
P/E ratio 2023
-10.8 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 54.32%
More Fundamentals * Assessed data
Dynamic Chart
Ocumetics Technology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ocumetics Technology Corp. announced that it has received CAD 0.4166 million in funding CI
Ocumetics Technology Corp. Announces Successful Completion of Animal Study in Preparation for Its First-In-Human Study, Anticipated to Commence in First Quarter of 2024 in the Dominican Republic CI
Ocumetics Technology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding CI
Ocumetics Continues to Meet Significant Development Milestones Lens Design Optimized for Upcoming First in Human Study CI
Ocumetics Technology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ocumetics Technology Corp. announced that it has received CAD 1 million in funding CI
Ocumetics Technology Corp. announced that it expects to receive CAD 1 million in funding CI
Ocumetics Technology Corp. Announces CEO Changes CI
Ocumetics Technology Corp. Announces Executive Changes CI
Ocumetics Technology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Ocumetics Technology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Ocumetics Technology Corp. Announces Resignation of Dr. Mark Lee as the President to Take Effect from June 30, 2023 CI
Ocumetics Technology Corp. Announces Resignation of Dr. Mark Lee as Chief Executive Officer, Effective from June 30, 2023 CI
More news
1 day+4.62%
1 week-1.45%
Current month+6.25%
1 month+15.25%
3 months-2.86%
6 months+6.25%
More quotes
1 week
0.31
Extreme 0.31
0.35
1 month
0.30
Extreme 0.3
0.35
Current year
0.25
Extreme 0.25
0.36
1 year
0.25
Extreme 0.25
0.40
3 years
0.24
Extreme 0.235
0.88
5 years
0.24
Extreme 0.235
0.88
10 years
0.24
Extreme 0.235
0.88
More quotes
Managers TitleAgeSince
Founder 69 12-04-11
Director of Finance/CFO 60 18-01-31
Chief Tech/Sci/R&D Officer - 21-09-30
Members of the board TitleAgeSince
Director/Board Member 68 21-01-31
Director of Finance/CFO 60 18-01-31
Founder 69 12-04-11
More insiders
Date Price Change Volume
24-04-25 0.345 +1.47% 1 000
24-04-24 0.34 +4.62% 1,500
24-04-22 0.325 -4.41% 24,799
24-04-19 0.34 +9.68% 16,000
24-04-18 0.31 -10.14% 23,000

Delayed Quote Toronto S.E., April 24, 2024 at 03:59 pm EDT

More quotes
Ocumetics Technology Corp. is a Canada-based research and product development company. The Company specializes in adaptive lens designs. The Company is focused on developing intraocular lens for people over 45 years of age. It is in the preclinical study stage of a technology for the ophthalmic industry. The Bionic Lens, which is an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to nearby. The Lens consists of self-adapting suspension systems that modulate curvature change. The Lens’s suspension systems are comprised of cushions that are designed to conform to unique parameters of each recipient’s eye. When ciliary muscles relax, during sleep or when the eye focuses upon distant objects, the optical interface is compressed into its high energy state by expansion of the suspension system.
More about the company